These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 33197333

  • 1. Heparin-mediated dimerization of follistatin.
    Walker RG, Kattamuri C, Goebel EJ, Zhang F, Hammel M, Tainer JA, Linhardt RJ, Thompson TB.
    Exp Biol Med (Maywood); 2021 Feb; 246(4):467-482. PubMed ID: 33197333
    [Abstract] [Full Text] [Related]

  • 2. Analysis of the interaction between heparin and follistatin and heparin and follistatin-ligand complexes using surface plasmon resonance.
    Zhang F, Beaudet JM, Luedeke DM, Walker RG, Thompson TB, Linhardt RJ.
    Biochemistry; 2012 Aug 28; 51(34):6797-803. PubMed ID: 22809401
    [Abstract] [Full Text] [Related]

  • 3. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions.
    Lerch TF, Shimasaki S, Woodruff TK, Jardetzky TS.
    J Biol Chem; 2007 May 25; 282(21):15930-9. PubMed ID: 17409095
    [Abstract] [Full Text] [Related]

  • 4. Anti-Müllerian hormone signaling is influenced by Follistatin 288, but not 14 other transforming growth factor beta superfamily regulators.
    Kawagishi Y, Pankhurst MW, Nakatani Y, McLennan IS.
    Mol Reprod Dev; 2017 Jul 25; 84(7):626-637. PubMed ID: 28500669
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.
    Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB.
    J Biol Chem; 2008 Nov 21; 283(47):32831-8. PubMed ID: 18768470
    [Abstract] [Full Text] [Related]

  • 7. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.
    Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA.
    Endocrinology; 2008 Sep 21; 149(9):4589-95. PubMed ID: 18535106
    [Abstract] [Full Text] [Related]

  • 8. Crystal structures of the heparan sulfate-binding domain of follistatin. Insights into ligand binding.
    Innis CA, Hyvönen M.
    J Biol Chem; 2003 Oct 10; 278(41):39969-77. PubMed ID: 12867435
    [Abstract] [Full Text] [Related]

  • 9. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
    Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A.
    Endocrinology; 2006 Jul 10; 147(7):3586-97. PubMed ID: 16627583
    [Abstract] [Full Text] [Related]

  • 10. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG).
    Schneyer A, Schoen A, Quigg A, Sidis Y.
    Endocrinology; 2003 May 10; 144(5):1671-4. PubMed ID: 12697670
    [Abstract] [Full Text] [Related]

  • 11. Follistatin Forms a Stable Complex With Inhibin A That Does Not Interfere With Activin A Antagonism.
    Kappes EC, Kattamuri C, Czepnik M, Yarawsky AE, Brûlé E, Wang Y, Ongaro L, Herr AB, Walton KL, Bernard DJ, Thompson TB.
    Endocrinology; 2023 Jan 09; 164(3):. PubMed ID: 36718082
    [Abstract] [Full Text] [Related]

  • 12. Structural basis for potency differences between GDF8 and GDF11.
    Walker RG, Czepnik M, Goebel EJ, McCoy JC, Vujic A, Cho M, Oh J, Aykul S, Walton KL, Schang G, Bernard DJ, Hinck AP, Harrison CA, Martinez-Hackert E, Wagers AJ, Lee RT, Thompson TB.
    BMC Biol; 2017 Mar 03; 15(1):19. PubMed ID: 28257634
    [Abstract] [Full Text] [Related]

  • 13. An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
    Muenster U, Harrison CA, Donaldson C, Vale W, Fischer WH.
    J Biol Chem; 2005 Nov 04; 280(44):36626-32. PubMed ID: 16129674
    [Abstract] [Full Text] [Related]

  • 14. Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.
    McCoy JC, Walker RG, Murray NH, Thompson TB.
    J Biol Chem; 2019 Apr 19; 294(16):6333-6343. PubMed ID: 30814254
    [Abstract] [Full Text] [Related]

  • 15. Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.
    Cash JN, Angerman EB, Kattamuri C, Nolan K, Zhao H, Sidis Y, Keutmann HT, Thompson TB.
    J Biol Chem; 2012 Jan 06; 287(2):1043-53. PubMed ID: 22052913
    [Abstract] [Full Text] [Related]

  • 16. Expression of activin A and follistatin core proteins by human prostate tumor cell lines.
    McPherson SJ, Mellor SL, Wang H, Evans LW, Groome NP, Risbridger GP.
    Endocrinology; 1999 Nov 06; 140(11):5303-9. PubMed ID: 10537161
    [Abstract] [Full Text] [Related]

  • 17. Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.
    Cash JN, Angerman EB, Keutmann HT, Thompson TB.
    Mol Endocrinol; 2012 Jul 06; 26(7):1167-78. PubMed ID: 22593183
    [Abstract] [Full Text] [Related]

  • 18. Muscle follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting.
    Nissinen TA, Hentilä J, Fachada V, Lautaoja JH, Pasternack A, Ritvos O, Kivelä R, Hulmi JJ.
    FASEB J; 2021 Mar 06; 35(3):e21387. PubMed ID: 33559263
    [Abstract] [Full Text] [Related]

  • 19. Structural basis for the inhibition of activin signalling by follistatin.
    Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvönen M.
    EMBO J; 2006 Mar 08; 25(5):1035-45. PubMed ID: 16482217
    [Abstract] [Full Text] [Related]

  • 20. Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells.
    Nakamura T, Sugino K, Titani K, Sugino H.
    J Biol Chem; 1991 Oct 15; 266(29):19432-7. PubMed ID: 1918055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.